The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts

Haematologica

Volumn 99, Issue 5, 2014, Pages 858-864

  Zabkiewicz, Joanna ^a   Pearn, Lorna ^a   Hills, Robert K ^a   Morgan, Rhys G ^a   Tonks, Alex ^a   Burnett, Alan K ^a   Darley, Richard L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; S6 KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIC INFILTRATION; MOLECULAR GENETICS; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL CULTURE; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PHOSPHORYLATION; PROGNOSIS;

CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84899745758     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096487     Document Type: Article

References (45)

1. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008; 35(4): 430-8.
2. Bayascas JR. PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol. Immunol. 2010; 346: 9-29.
3. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004; 15(2): 161-70.
4. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006; 20(6): 911-28.
5. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med. 2007; 13(6): 252-9.
6. Tessier M, Woodgett JR. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem. 2006; 98(6): 1391-407.
7. Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007; 12(3): 201-14.
8. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7(4): 281-94.
9. Williams MR, Arthur JS, Balendran A, van der KJ, Poli V, Cohen P, et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol. 2000; 10(8): 439-48.
10. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 2000; 484(3): 217-23.
11. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell. 2000; 103(2): 185-8.
12. Biondi RM. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem Sci. 2004; 29(3): 136-42.
13. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J. 2003; 370(Pt 2): 361-71.
14. Nakamura K, Sakaue H, Nishizawa A, Matsuki Y, Gomi H, Watanabe E, et al. PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression. J Biol Chem. 2008; 283(25): 17702-11.
15. Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol. 2008; 10(2): 127-37.
16. Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol. 2000; 10(22): 1439-42.
17. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 2002; 21(14): 3728-38.
18. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol. 2005; 15(20): 1839-46.
19. Tamguney T, Zhang C, Fiedler D, Shokat K, Stokoe D. Analysis of 3-phosphoinositidedependent kinase-1 signaling and function in ES cells. Exp Cell Res. 2008; 314(11-12): 2299-312.
20. Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer. 2005; 93(12): 1372-81.
21. Ahmed N, Riley C, Quinn MA. An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br J Cancer. 2008; 98(8): 1415-24.
22. Yang KJ, Shin S, Piao L, Shin E, Li Y, Park KA, et al. Regulation of 3-phosphoinositidedependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem. 2008; 283(3): 1480-91.
23. Yu J, Chen KS, Li YN, Yang J, Zhao L. Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer. Asian Pac J Cancer Prev. 2012; 13(8): 4147-51.
24. Iorns E, Lord CJ, Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009; 417(1): 361-70.
25. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013; 23(3): 406-20.
26. Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. Chem Med Chem. 2008; 3(12): 1810-38.
27. Pearn L, Fisher J, Burnett AK, Darley RL. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood. 2007; 109(10): 4461-9.
28. Darley RL, Pearn L, Omidvar N, Sweeney M, Fisher J, Phillips S, et al. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood. 2002; 100(12): 4185-92.
29. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 2013; 32(2): 135-40.
30. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest. 2011; 121(1): 384-95.
31. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10): 1777-84.
32. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005; 280(20): 19867-74.
33. Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 2008; 68(7): 2223-32.
34. Rodriguez OC, Lai EW, Vissapragada S, Cromelin C, Avetian M, Salinas P, et al. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol. 2009; 174(6): 2051-60.
35. Kikani CK, Verona EV, Ryu J, Shen Y, Ye Q, Zheng L, et al. Proliferative and antiapoptotic signaling stimulated by nuclear-localized PDK1 results in oncogenesis. Sci Signal. 2012; 5(249): ra80.
36. Xie Z, Zeng X, Waldman T, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res. 2003; 63(17): 5370-5.
37. Liu J, Wang Y, Birnbaum MJ, Stoffers DA. Three-amino-acid-loop-extension homeodomain factor Meis3 regulates cell survival via PDK1. Proc Natl Acad Sci USA. 2010; 107(47): 20494-9.
38. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009; 16(1): 21-32.
39. Najafov A, Sommer EM, Axten JM, Deyoung MP, Alessi DR. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2010; 433(2): 357-69.
40. Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res. 2002; 62(12): 3538-43.
41. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, et al. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000; 6(4): 1401-9.
42. Schepers H, Geugien M, Eggen BJ, Vellenga E. Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia. Leukemia. 2003; 17(11): 2113-21.
43. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006; 3(8): 448-57.
44. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006; 66(7): 3737-46.
45. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem. 2011; 11(3): 185-99.